All In Biotech

Drug Trial Radar · NCT05195632

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

Jun 2, 2022

Primary completion

May 27, 2024

Study completion Dec 14, 2026

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Jan 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either previously untreated or have had one line of prior therapy in metastatic setting.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • EncorafenibDrug

    Hard capsule

  • BinimetinibDrug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-In (SLI) Part: Incidence of Dose-limiting toxicities (DLTs)Time frame: Cycle 1; Each cycle is 28 days
  2. Pivotal Part: Confirmed objective response rate (cORR)Time frame: Cycle 1 Day 1 through safety follow-up visit (30 days after end of treatment (EOT) visit or 7 days after EOT visit/last dose if EOT not performed), approximately up to 18 months. Each cycle is 28 days.

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • The Second Hospital of Dalian University

    Dalian, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)

    Fuzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Hainan General Hospital

    Haikou, China

  • First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Zhejiang University School of Medicine, Sir Run Run Shaw Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Shandong Cancer Hospital

    Jinan, China

  • The First Affiliated Hospital of Jinzhou Medical University

    Jinzhou, China

  • Linyi Cancer Hospital

    Linyi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, China

  • The First Hospital of China Medical University

    Shenyang, China

  • Peking University Shenzhen Hospital

    Shenzhen, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Union Hospital Tongji medical college Huazhong University of Science and Technology

    Wuhan, China

  • The Northern Jiangsu People's Hospital

    Yangzhou, China

  • Yantai Yuhuangding Hospital

    Yantai, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.